. Erratum: Trastuzumab Deruxtecan in Patients With HER2-Mutant Metastatic Non-Small-Cell Lung Cancer: Primary Results From the Randomized, Phase II DESTINY-Lung02 Trial. J Clin Oncol 2023 Dec 19:JCO2302574. doi: 10.1200/JCO.23.02574.
PMID: 38113428